Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 18/20 | 0.62 |
| ▸ | RARB | P10826 | 18/20 | 0.62 |
| ▸ | RARG | P13631 | 18/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132581 | 1.00 | RARA (0.62) | RARARARBRARG | |
| SCHEMBL7623083 | 0.90 | RARA (0.63) | RARARARBRARG | |
| SCHEMBL7617714 | 0.90 | RARA (0.53) | RARARARBRARG | |
| SCHEMBL7619645 | 0.90 | RARA (0.63) | RARARARBRARG | |
| SCHEMBL6049832 | 0.89 | RARA (0.51) | RARARARBRARG | |
| SCHEMBL7624800 | 0.89 | RARA (0.53) | RARARARBRARG | |
| SCHEMBL7623971 | 0.89 | RARB (0.55) | RARARARBRARG | |
| SCHEMBL7949929 | 0.88 | RARA (0.50) | RARARARBRARG | |
| SCHEMBL7624517 | 0.88 | RARA (0.48) | RARARARBRARG | |
| SCHEMBL7624482 | 0.88 | RARA (0.50) | RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12409191-B2 | Renal cell populations and uses thereof | PROKIDNEY (KY) | 2025-09-09 | — | — | US | disclosed |
| EP-3901251-B9 | RENAL CELL POPULATIONS AND USES THEREOF | PROKIDNEY (KY) | 2025-06-18 | — | — | EP | disclosed |
| US-20250152632-A1 | RENAL CELL POPULATIONS AND USES THEREOF | ProKidney IPCo, LLC (KY) | 2025-05-15 | — | — | US | disclosed |
| EP-4527921-A2 | RENAL CELL POPULATIONS AND USES THEREOF | ProKidney (KY) | 2025-03-26 | — | — | EP | disclosed |
| EP-3233842-B1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARB) AGONISTS | KING S COLLEGE LONDON (GB) | 2025-03-26 | — | — | EP | disclosed |
| EP-3901251-B1 | RENAL CELL POPULATIONS AND USES THEREOF | PROKIDNEY (KY) | 2024-12-25 | — | — | EP | disclosed |
| US-20240409941-A1 | BIOACTIVE RENAL CELLS | ProKidney IPCo, LLC (KY) | 2024-12-12 | — | — | US | disclosed |
| US-12157887-B2 | Bioactive renal cells | PROKIDNEY (KY) | 2024-12-03 | — | — | US | disclosed |
| EP-3452032-B1 | RARA AGONISTS FOR THE TREATMENT OF AML AND MDS | SYROS PHARMACEUTICALS INC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4403197-A2 | INJECTABLE FORMULATIONS FOR ORGAN AUGMENTATION | ProKidney (KY) | 2024-07-24 | — | — | EP | disclosed |
| US-11447831-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | SYROS PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220249569-A1 | ORGANOIDS COMPRISING ISOLATED RENAL CELLS AND USES THEREOF | ProKidney IPCo, LLC (KY) | 2022-08-11 | — | — | US | disclosed |
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON | 2022-08-02 | — | — | US | disclosed |
| US-20220202867-A1 | TREATMENT OF KIDNEY DISEASE IN SUBJECTS WITH KIDNEY AND/OR URINARY TRACT ANOMALIES | ProKidney IPCo, LLC (KY) | 2022-06-30 | — | — | US | disclosed |
| US-11369639-B2 | Renal cell populations and uses thereof | PROKIDNEY (KY) | 2022-06-28 | — | — | US | disclosed |
| CN-114390925-A | Treating nephropathy in a subject having renal and/or urinary tract abnormalities | 蒂莫西.伯特伦 | 2022-04-22 | — | — | CN | disclosed |
| EP-3967305-A1 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | Syros Pharmaceuticals, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3962500-A1 | TREATMENT OF KIDNEY DISEASE IN SUBJECTS WITH KIDNEY AND/OR URINARY TRACT ANOMALIES | Bertram, Timothy, A. (KY) | 2022-03-09 | — | — | EP | disclosed |
| CN-109415356-B | Crystalline forms of 4- (5- (4, 7-dimethylbenzofuran-2-yl) -1,2, 4-oxadiazol-3-yl) benzoic acid and methods for their preparation | 伦敦皇家学院 | 2022-03-08 | — | — | CN | disclosed |
| CN-107823706-B | Injectable formulation for organ augmentation | 因瑞金公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 4/4885 |
| US-11447831-B2 | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.